Nutraceutical provider Unibar Corporation has secured a novel European patent for its flagship eye health ingredient, CapsiClear.
Derived from the chilli pepper Capsicum annum, CapsiClear is standardised to 50% capsanthin, a carotenoid touted for its ability to assist with ocular pressure.
Through the granting of this European patent, CapsiClear can be exclusively used for the reduction of intraocular pressure associated with:
- Normal tension glaucoma
- Primary open angle glaucoma
- Angle closure glaucoma
- Combinations of the above
This patent covers key European markets, including France, Germany, Italy, Spain Switzerland, the UK, Greece, Hungary, Ireland and Poland — facilitating Unibar's continued international growth.
By surpassing this regulatory milestone, Unibar has also offered itself a leg up for its strategic marketing efforts; particularly ahead of upcoming industry events such as IFT FIRST and Natural Products Expo West.
Combatting dry eye
Dry eye is a highly prevalent affliction worldwide, with up to 30% of Europeans experiencing the condition.
As we progress further into the digital world, dry eye is also on the rise — with increased screen time exacerbating symptoms.
Systemic health issues, poor sleep and the natural ageing process can also be highly detrimental to eye health, so developing science-backed nutraceutical solutions to address these issues is key.
"Despite its impact on daily comfort and productivity, dry eye remains under-recognised and often under-addressed. This patent decision validates CapsiClear's efficacy for eye hydration, and will offer true product differentiation to supplement brands throughout Europe," noted Unibar's President, Sevanti Mehta.
Following the granting of this patent, Unibar is preparing a series of targeted marketing campaigns to introduce CapsiClear to global partners, formulators and health professionals — with launches expected ahead of major industry conferences this autumn.